Search CORE

21 research outputs found

Leflunomide: less toxic than standard therapy for lupus nephritis?

Author: Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

The secret of successful long-term gout therapy

Author: Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Predicting RA progression

Author: Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

No VTE risk with bisphosphonates

Author: Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Kidney damage is a key predictor of mortality in SLE

Author: Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Teriparatide or alendronate for glucocorticoid-induced osteoporosis therapy?

Author: KG Saag
Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Sustaining remission in juvenile dermatomyositis

Author: Kim S.
Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Time to give up on chemokine receptor antagonism for RA therapy?

Author: CE Vergunst
Negin Nassabeh
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Is CD70 a new therapeutic target?

Author: Negin Nassabeh
Oflazoglu E.
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Polymyositis therapy: is there a place for IL-6 blockade?

Author: Negin Nassabeh
Okiyama N.
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

core

core